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0.70; 95% CI 0.54 - 0.92, p < 0.001 ). Thus, abciximab prevented 44 events (xl000). 
Conclusions. Optimal mechanical reperfusion in acute MI is provided by stent placement 
and GP lib/Ilia use, with a 30% odd reduction in the composite end point. 
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883-2 Ef fect  of  Stent  Imp lantat ion  and Glycoprotein l ib/I l ia 
Receptor Blockade on Target Vessel Revascularization 
in Diabetics After Primary PCl in Acute Myocardial 
Infarction: The CADILLAC TRIAL 
Thomas D. Stuckev. Cindy L. Gdnes, Bruce R. Brodie, David A. Cox, John J. Griffin, 
John Carroll, Giulio Guagliumi, Eulogio Garcia, Barry Rutherford, Mark Turco, James E. 
Tcheng, Gregg W. Stone, LeBauer Cardiovascular Research Foundation and Moses 
Cone Heart & Vascular Center, Greensboro, North Carolina. 
Background: Rates of TVR are increased in pts with diabetes mellitus (DM) following 
PCI. In a large randomized tdal of elective PCi (EPISTENT), the addition of abciximab 
(Abcx) to stenting resulted in TVR rates in DM similar to that of non-DM, and lower than 
that in DM without Abcx. We sought to verify this relationship in a large study of pts 
undergoing stenting in AMI. 
Method: In the CADILLAC trial, 2,082 pts of any age with AMI <12 hours in duration with- 
out cardiogenic shock were randomized to pdmary PTCA, PTCA + Abcx, stent implanta- 
tion, or stenting + Abcx. DM was present in 346 pts (16.6%). 
Results: Compared to non DM pts, ischemic TVR tended to occur more often in DM 
(12.0% vs. 9.2%, p=O.10). Pooling all diabetic pts assigned to Abcx vs. no Abcx, the 6 
month rate of subacute thrombosis was 1.86% vs. 0% respectively (p=0.10), and 
ischemic TVR occurred in 10.1% vs. 12.2% (p=0.58). 6 month TVR rates in DM stratified 
by the 4 randomization arms appear in the table. 
Compared to pts randomized to PTCA, 6 month iscbemic TVR in diabetics randomized to 
routine slanting was reduced (7.2% vs. 17.7%, p=0.004). Furthermore, the 6 month rate 
of ischemic TVR in stentad diabetics was similar to that in non diabetics (7.2% vs. 5.9%, 
p=NS). 
Conclusions: Whereas Abcx may reduce the rate of subacute thrombosis in diabetic pts 
undergoing primary PCI in AMI, Abcx had no significant effect on clinical restenosis 
(ischemic TVR) or any TVR. In contrast, a strategy of routine stent implantation signifi- 
cantly reduced TVR rates in DM independent of Abcx use. 
PTCA PTCA/ Stent StentJ p Value 
Abcx Abcx 
(n=79) (n=82) (n=83) (n=101) 
SAT 2.5% 0% 1.2% 0% 0.24 
Ichemic TVR 19.2% 16.2% 7.4% 7.0% 0.03 
I-PCI 15.3% 11.2% 4.9% 4.0% 0.02 
I-CABG 3.8% 5.0% 2,5% 3.0% 0.83 
Any TVR 25.6% 28.4% 14,8% 18.8% 0.12 
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883-3 Angiographic Determinants of Infarct Size After 
Successful Percutaneous Intervention for Acute ST-T 
Elevation Myocardial Infarction: The Impact of Distal  
Embolization 
Jose P. Henrioues. Felix Zijlstre, Jan Paul Ottervanger, Menko-Jan de Boer, Jan-Henk E. 
Dambrink, Arnoud W. van 't Hof, Jan C, Hoorntje, Harry Suryapranata, Isala Klinieken, 
Hosp. De Weezen/anden, Zwolle, The Netherlands. 
Background: Angiographic variables may predict infarct size and prognosis in patients 
(pts) with acute myocardial infarction (MI). Previously, we demonstrated that distal embo- 
lization resulted in more extensive myocardial damage and impaired clinical outcome. In 
this study we investigated the value of distal embolization and other angiographic deter- 
minants, to predict the extent of myocardial damage after successful primary angiopiasty. 
Methods: Angiographic data were assessed on the coronary angiogram made immedi- 
ately after successful coronary angiopLasty in 631 consecutive pts with acute MI. Infarct 
artery, TIMI flow, myocardial blush grade have previously been described. Embolization 
was defined as a distal filling defect with an abrupt 'cutoff' in 1 of the peripheral coronary 
artery branches of the infarct-related vessel, distal to the site of angioplasty. Endpoints 
were left ventricular ejection fraction (LVEF) and enzymatic infarct size as measured by 
cumulative lactate dehydrogenase enzyme release during 48 h (LDHQ48). 
Results: LAD related MI, impaired myocardial blush and presence of distal embolization 
were independent predictors of more extensive myocardial damage. Distal embolization 
was present in 102 pts (16%) and was associated with a large enzymatic infarct size 
(LDHQ48 2250 vs. 1532, p = 0.001) and a lower LVEF (41% vs. 44%, p = 0.041). Intrac- 
oronary stents were used in 80% of the pts. The frequency of distal embolization was not 
different between pts treated with or without stents. 
Conclusion: In pts with successful primary angioplasty, LAD related MI, impaired myocar- 
dial blush and presence of distal embolization are independent predictors of more exten- 
sive myocardial damage. Intracoronary stenting is not associated with more distal 
embolization during primary angioplasty. Distal embolization can be visualized in 16% of 
pts and is associated with a larger enzymatic infarct size and lower LVEF. 
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Does Optimal or Stent-Like PTCA Provide Equivalent 
Outcomes Compared to Primary Stentlng in Acute 
Myocardial Infarction? Early and Late Results From the  
CADILLAC Trial 
David A. Cox. Cindy Grines, Eulogio Gareia, Thomas Btuckey, James Teheng, Giulio 
Guagliumi, Adeyemi Johnson, Alexandra Lansky, ,John Griffin, Gregg W. Stone, Mid 
Carolina Cardiology, Charlotte, NC, The Cardiovascular Research Foundation, New York 
City, New York. 
Background: In Stent PAMI, optimal PTCA results did not produce equivalent long-term 
outcomes compared to stenting. However, abciximab was administered to only 5% of 
PTCA pts in this trial. Whether optimal PTCA with abciximab would provide equivalent 
outcomes to stanting is unknown. 
Methods: In the CADILLAC trial, 2082 AMI pts of any age presenting w/in 12 hours of 
symptom onset (excl. cardiogenic shock) were randomized at 76 sites to primary PTCA, 
PTCA with abciximab, stent alone, or stent with abcix. Optimal PTCA was defined as 
QCA diameter stenosis<30% w/out significant dissection in patients who did not receive 
a bail-out stent. 
Results: By core lab analysis, 51.2% (509/994) of PTCA pts had an optimal result, 
including 61.8% vs 59.2% of those assigned to abciximab vs. no abcix, respectively 
(p=NS). At 30 days no significant differences were apparent between pts achieving opti- 
mal PTCA results and those randomized to stenting with respect to death, reinfarction, 
ischemic TVR, SAT, and MACE. 1-year clinical outcomes appear in the Table. 
Conclusion: An optimal ballon angioplasty result may be obtained in a significant per- 
centage of patients undergoing AMI intervention. However, compared to a routine stent 
strategy, pts achieving an optimal PTCA result have greater 1-year rates of ischemie 
"I'VR and MACE. Abciximab did not significantly improve short or long-term outcomes in 
pts achieving optimal PTCA. Thus, in AMI, pdmary stenting provides better long-term 
outcomes even when an optimal PTCA resutt is obtained. 
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Opt PTCA w/out abcix Opt PTCA w/abcix All Optimal PTCA All Stent 
N 239 270 509 1014 
Death 4.2% 2.6% 3.3% 4.3% 
Reinfarction 0.8% 2.2% 1.6% 2.0 
Ischemic TVR 13.4% 19.3% 16.5% 7.9%* 
MACE 17.2% 21.9% 19.7% 13.0%* 
*p<.001 All opt PTCA vs stent 
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883-5 The  Salutary  Ef fect  of Prior Beta Blocker Therapy on 
Cl in ica l  Outcomes Following Primary Angioplesty for 
Acute Myocardial infarction: A Pooled Analysis From 
the Primary Angioplasty in Myocardial Infarction 
(PAMhl), PAMh2, and Stent:PAMI Trials 
Kishore J. Hadai. Gregg W. Stone, Judith Boura, Lorelei Grines, Eulogia Garcia, Bruce 
Brodie, David Cox, William W. O'Neill, Cindy Grines, William Beaumont Hospital, Royal 
Oak, Michigan. 
Background: Beta-blockers (BB) have anti-adrenergic, anti-ischemic, and anti-arrhyth- 
mic properties. We hypothesized that pre-treatment with BB would have a beneficial 
effect on clinical outcomes in patients undergoing primary angioplasty for acute myocar- 
dial infarction. 
Methods: We pooled clinical, angiographic, and outcomes data on 2537 patients 
enrolled in the Primary Angioplasty in Myocardial Infarction (PAMI-1), PAMI-2, and Stent 
PAMI trials. We classified patients into BB group (n=1132) if they received BB before 
undergoing percutaneous coronary intervention (PCI), or No-BB group (n=1405) if not. 
We studied the incidence of procedural complications, in-hospital and 1-year outcomes 
[death and composite end-point of death, re-infarction, target vessel revasculadzation, or 
stroke] between the 2 groups, 
Results: BB patients were younger, had higher systolic blood pressure and heart rate, 
and were more likely to have Killip Class I at admission than no-BB patients. Further, 
they had lower ejection fraction, higher door-to balloon time. and were more likely to 
have the left anterior descending artery as the infarct-related artery. Although BB patients 
had more spontaneous patency (baseline TIM I 2-3 flow 30 Vs 21%, p<0.0001), they had 
similar incidence of TIMI-3 flow following PCI (92.6 vs 92.7%). Pre-treatment with BB 
was associated with lower incidence of procedural complications (23 vs. 34%, 
p<0.0001), primarily due to less ventdcular arrhythmias (4 Vs 7%, p=0.004) and brady- 
arrhythmias (8 Vs 17%, p<0.0001). BB patients had lower incidence of death (1.6 Vs 
3.7%, p=0.0035) and the composite end-point (5.3 vs. 7.6%, p=0.022) during hospitaliza- 
tion. At 1-year, the incidence of death remained lower in BB patients (4.8 vs. 6.7%, 
p=0.042). After adjustment for baseline clinical and angiographic differences, BB patients 
had a lower probability of death during hospitalization (odds ratio, OR=0.41; 95% 
C1=0.20-0.84; p<0.0148) and at 1-year (OR=0.67; C1=0.43-1.03; p=0.069). 
Conclusion: Pre-treatment with BB has an independent salutary effect on short-term 
and intermediate-tarm clinical outcomes in patients undergoing primary angioplasty for 
acute myocardial infarction. 
